Genetic Interactions of STAT3 and Anticancer Drug Development (Q38198930)

30 August 2017

Genetic Interactions of STAT3 and Anticancer Drug Development (English)

1 reference

30 August 2017

Bingliang Fang

1

1 reference

30 August 2017

6 March 2014

1 reference

30 August 2017

1 reference

30 August 2017

6

1 reference

30 August 2017

494-525

1 reference

30 August 2017

1

1 reference

Creative Commons Attribution 4.0 International

30 August 2017

start time

6 March 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Maintenance of tumor initiating cells of defined genetic composition by nucleostemin

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

STATs in cancer inflammation and immunity: a leading role for STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Stattic: a small-molecule inhibitor of STAT3 activation and dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Design, synthesis, and studies of small molecule STAT3 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Small molecule inhibitors of Stat3 signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Targeting the interleukin-6/Jak/stat pathway in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Intermittent preventive therapy for malaria during pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in Africa: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Design and discovery of small molecules targeting raf-1 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Expression of AFP and STAT3 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in AFP-producing gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Gold(I) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Diverse somatic mutation patterns and pathway alterations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

A comprehensive catalogue of somatic mutations from a human cancer genome

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Is the focus moving toward a combination of targeted drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Molecular basis for sunitinib efficacy and future clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

The STAT3 isoforms alpha and beta have unique and specific functions

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Stat3 isoforms, alpha and beta, demonstrate distinct intracellular dynamics with prolonged nuclear retention of Stat3beta mapping to its unique C-terminal end.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Diffuse large B cell lymphoma in hyper-IgE syndrome due to STAT3 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Non-Hodgkin's lymphoma in Job's syndrome: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Constitutive activation of STAT3 and STAT5 is present in the majority of nasopharyngeal carcinoma and correlates with better prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Stat3 promotes metastatic progression of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Clinical value of signal transducers and activators of transcription 3 (STAT3) gene expression in human osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Tyrosine kinase ETK/BMX is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

WT1: a weak spot in KRAS-induced transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Synthetic lethal screen identification of chemosensitizer loci in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Use of isogenic human cancer cells for high-throughput screening and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Modeling synthetic lethality.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Global synthetic-lethality analysis and yeast functional profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Jak2 is essential for signaling through a variety of cytokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Activation of STAT proteins and growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Stats: transcriptional control and biological impact

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Mitochondrial STAT3 supports Ras-dependent oncogenic transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Live cell imaging of interleukin-6-induced targeting of "transcription factor" STAT3 to sequestering endosomes in the cytoplasm.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Oncogenically active MYD88 mutations in human lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Requirement of serine phosphorylation for formation of STAT-promoter complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Serine phosphorylation and negative regulation of Stat3 by JNK

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Stat3 dimerization regulated by reversible acetylation of a single lysine residue

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

STAT3 inhibition of gluconeogenesis is downregulated by SirT1

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

PTP1B regulates leptin signal transduction in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

A new protein containing an SH2 domain that inhibits JAK kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Structure and function of a new STAT-induced STAT inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

A nuclear protein tyrosine phosphatase is required for the inactivation of Stat1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Specific inhibition of Stat3 signal transduction by PIAS3

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

A Drosophila PIAS homologue negatively regulates stat92E

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Ras and Rho GTPases: a family reunion

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Human RAS superfamily proteins and related GTPases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

GAP control: regulating the regulators of small GTPases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Overexpression of c-K-ras, c-N-ras and transforming growth factor beta co-segregate with tumorigenicity in morphologically transformed C3H 10T1/2 cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Distinct mechanisms determine the patterns of differential activation of H-Ras, N-Ras, K-Ras 4B, and M-Ras by receptors for growth factors or antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Mammalian Ras interacts directly with the serine/threonine kinase Raf

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Phosphatidylinositol-3-OH kinase as a direct target of Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

RAS is regulated by the let-7 microRNA family

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Suppression of non-small cell lung tumor development by the let-7 microRNA family

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Ras mediates effector pathways responsible for pre-B cell survival, which is essential for the developmental progression to the late pre-B cell stage

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Signaling from Ras to Rac and beyond: not just a matter of GEFs

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

The R(h)oads to Stat3: Stat3 activation by the Rho GTPases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Rho family GTPases are required for activation of Jak/STAT signaling by G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Regulation of STAT3 by direct binding to the Rac1 GTPase

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Rac1 mediates STAT3 activation by autocrine IL-6

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Activated Rac1 requires gp130 for Stat3 activation, cell proliferation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

A role of STAT3 in Rho GTPase-regulated cell migration and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

STAT3 mediates resistance to MEK inhibitor through microRNA miR-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Diverse mechanisms of somatic structural variations in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Pyk2 amplifies epidermal growth factor and c-Src-induced Stat3 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

An EGF receptor/Ral-GTPase signaling cascade regulates c-Src activity and substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

In vitro activation of Stat3 by epidermal growth factor receptor kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Phosphotyrosine 1173 mediates binding of the protein-tyrosine phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Distinct mechanisms of activation of Stat1 and Stat3 by platelet-derived growth factor receptor in a cell-free system

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Targeting Stat3 abrogates EGFR inhibitor resistance in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Free radicals in the physiological control of cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Reactive oxygen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Requirement for generation of H2O2 for platelet-derived growth factor signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Reactive oxygen species are downstream mediators of p53-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Radical causes of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Ferritin heavy chain-mediated iron homeostasis and subsequent increased reactive oxygen species production are essential for epithelial-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Thioredoxin-like 2 regulates human cancer cell growth and metastasis via redox homeostasis and NF-κB signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Reactive oxygen generated by Nox1 triggers the angiogenic switch

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Association of reactive oxygen species levels and radioresistance in cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Src-mediated tyrosine phosphorylation of p47phox in hyperoxia-induced activation of NADPH oxidase and generation of reactive oxygen species in lung endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Cell membrane oxidative damage induced by gamma-radiation and apoptotic sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Membrane oxidative damage and apoptosis in cervical carcinoma cells of patients after radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Oxidative stress triggers STAT3 tyrosine phosphorylation and nuclear translocation in human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Interleukin-11 links oxidative stress and compensatory proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Evidence that IL-6-type cytokine signaling in cardiomyocytes is inhibited by oxidative stress: parthenolide targets JAK1 activation by generating ROS

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Excessive nitric oxide attenuates leptin-mediated signal transducer and activator of transcription 3 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Nitric oxide and thiol redox regulation of Janus kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Multiple cysteine residues are implicated in Janus kinase 2-mediated catalysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

S-glutathionylation impairs signal transducer and activator of transcription 3 activation and signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Disruption of astrocyte STAT3 signaling decreases mitochondrial function and increases oxidative stress in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Mitochondrial-targeted Signal transducer and activator of transcription 3 (STAT3) protects against ischemia-induced changes in the electron transport chain and the generation of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Antagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Oxidative stress in NSC-741909-induced apoptosis of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Phase III and submission failures: 2007–2010

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Trial watch: Phase II failures: 2008-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Regulation of interferon-alpha responsiveness by the duration of Janus kinase activity

21 January 2018

2 references

https://api.crossref.org/works/10.3390%2FCANCERS6010494

21 January 2018

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis.

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Activation of STAT3 is a marker of poor prognosis in human colorectal cancer

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Redox regulation of the G1 to S phase transition in the mouse embryo fibroblast cell cycle.

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Cellular thiols and reactive oxygen species in drug-induced apoptosis

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Activation of the JAK-STAT pathway by reactive oxygen species.

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Induction of cyclin D1 overexpression by activated ras.

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

A novel cytokine-inducible gene CIS encodes an SH2-containing protein that binds to tyrosine-phosphorylated interleukin 3 and erythropoietin receptors

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Grb2/Ash binds directly to tyrosines 1068 and 1086 and indirectly to tyrosine 1148 of activated human epidermal growth factor receptors in intact cells

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Auranofin therapy in rheumatoid arthritis.

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Stability of c-K-ras amplification during progression in a patient with adenocarcinoma of the ovary.

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Production of large amounts of hydrogen peroxide by human tumor cells

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C gamma

5 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3980611

Electron Transfer between Cytochrome c and p66Shc Generates Reactive Oxygen Species that Trigger Mitochondrial Apoptosis

5 November 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS6010494

Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival

21 January 2018

1 reference

12 December 2020

Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer

1 reference

12 December 2020

Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis

1 reference

12 December 2020

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

12 December 2020

Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma

1 reference

12 December 2020

Insulin-like growth factor-I (IGF-I) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species

1 reference

12 December 2020

The state of innovation in drug development

1 reference

12 December 2020

Activation of the signal transducers and activators of the transcription 3 pathway in alveolar epithelial cells induces inflammation and adenocarcinomas in mouse lung

1 reference

12 December 2020

Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3

1 reference

12 December 2020

Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis

1 reference

12 December 2020

Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma

1 reference

12 December 2020

An adolescent with marked hyperimmuno-globulinemia E showing minimal change nephrotic syndrome and a STAT3 gene mutation

1 reference

12 December 2020

Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS)

1 reference

12 December 2020

Stat3 promotes directional cell migration by regulating Rac1 activity via its activator betaPIX

1 reference

12 December 2020

Inverse association between Raf Kinase Inhibitory Protein and signal transducers and activators of transcription 3 expression in gastric adenocarcinoma patients: implications for clinical outcome

1 reference

12 December 2020

Destructive pulmonary staphylococcal infection in a boy with hyper-IgE syndrome: a novel mutation in the signal transducer and activator of transcription 3 (STAT3) gene (p.Y657S)

1 reference

12 December 2020

Targeting STAT3 in cancer: how successful are we?

1 reference

12 December 2020

c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability

1 reference

12 December 2020

Identifiers

DOI

10.3390/CANCERS6010494

1 reference

30 August 2017

0 references

1 reference

PubMed ID

24662938